Skip to main content
. 2021 Sep 2;147(10):1–8. doi: 10.1001/jamaoto.2021.2191

Figure 2. Efficacy Evaluation of Neoadjuvant Immunotherapy for Resectable Head and Neck Cancer.

Figure 2.

Pathological complete response (A) and major pathological response (B) at the primary tumor sites in clinical trials. PD-1/PD-L1 indicates programmed cell death 1/programmed cell death 1 ligand 1.